391 related articles for article (PubMed ID: 32866691)
1. N-terminal pro-B-type natriuretic peptide is a specific predictor of appropriate device therapies in patients with primary prevention implantable cardioverter-defibrillators.
Sroubek J; Matos J; Locke A; Kaplinskiy V; Levine YC; Shen C; Buxton AE
Heart Rhythm; 2021 Jan; 18(1):71-78. PubMed ID: 32866691
[TBL] [Abstract][Full Text] [Related]
2. B-type natriuretic peptide is a major predictor of ventricular tachyarrhythmias.
Levine YC; Rosenberg MA; Mittleman M; Samuel M; Methachittiphan N; Link M; Josephson ME; Buxton AE
Heart Rhythm; 2014 Jul; 11(7):1109-16. PubMed ID: 24837348
[TBL] [Abstract][Full Text] [Related]
3. Increased N-terminal-pro-B-type natriuretic peptide levels in patients with appropriate implantable defibrillator therapies.
Arnaldo FJ; Anatoliotakis N; Palacio C; Nabert DR; Hsu SS
Heart Lung; 2009; 38(1):10-6. PubMed ID: 19150526
[TBL] [Abstract][Full Text] [Related]
4. Amino-terminal pro-brain natriuretic peptide predicts ventricular arrhythmogenesis in patients with ischemic cardiomyopathy and implantable cardioverter-defibrillators.
Manios EG; Kallergis EM; Kanoupakis EM; Mavrakis HE; Kambouraki DC; Arfanakis DA; Vardas PE
Chest; 2005 Oct; 128(4):2604-10. PubMed ID: 16236931
[TBL] [Abstract][Full Text] [Related]
5. LGE and NT-proBNP identify low risk of death or arrhythmic events in patients with primary prevention ICDs.
Mordi I; Jhund PS; Gardner RS; Payne J; Carrick D; Berry C; Tzemos N
JACC Cardiovasc Imaging; 2014 Jun; 7(6):561-9. PubMed ID: 24813968
[TBL] [Abstract][Full Text] [Related]
6. N-terminal pro-B-type natriuretic peptide for prediction of ventricular arrhythmias: Data from the SMASH study.
Sourour N; Riveland E; Naesgaard P; Kjekshus H; Larsen AI; Omland T; Røsjø H; Myhre PL
Clin Cardiol; 2023 Aug; 46(8):989-996. PubMed ID: 37400982
[TBL] [Abstract][Full Text] [Related]
7. Protein biomarkers identify patients unlikely to benefit from primary prevention implantable cardioverter defibrillators: findings from the Prospective Observational Study of Implantable Cardioverter Defibrillators (PROSE-ICD).
Cheng A; Zhang Y; Blasco-Colmenares E; Dalal D; Butcher B; Norgard S; Eldadah Z; Ellenbogen KA; Dickfeld T; Spragg DD; Marine JE; Guallar E; Tomaselli GF
Circ Arrhythm Electrophysiol; 2014 Dec; 7(6):1084-91. PubMed ID: 25273351
[TBL] [Abstract][Full Text] [Related]
8. NT-proBNP and ICD in Nonischemic Systolic Heart Failure: Extended Follow-Up of the DANISH Trial.
Butt JH; Yafasova A; Elming MB; Dixen U; Nielsen JC; Haarbo J; Videbæk L; Korup E; Bruun NE; Eiskjær H; Brandes A; Thøgersen AM; Gustafsson F; Egstrup K; Hassager C; Svendsen JH; Høfsten DE; Torp-Pedersen C; Pehrson S; Thune JJ; Køber L
JACC Heart Fail; 2022 Mar; 10(3):161-171. PubMed ID: 35241243
[TBL] [Abstract][Full Text] [Related]
9. The prognostic value of repeated measurement of N-terminal pro-B-type natriuretic peptide in patients with chronic heart failure due to left ventricular systolic dysfunction.
Kubánek M; Goode KM; Lánská V; Clark AL; Cleland JG
Eur J Heart Fail; 2009 Apr; 11(4):367-77. PubMed ID: 19179406
[TBL] [Abstract][Full Text] [Related]
10. Defining potential to benefit from implantable cardioverter defibrillator therapy: the role of biomarkers.
Scott PA; Townsend PA; Ng LL; Zeb M; Harris S; Roderick PJ; Curzen NP; Morgan JM
Europace; 2011 Oct; 13(10):1419-27. PubMed ID: 21784745
[TBL] [Abstract][Full Text] [Related]
11. Comparison of N-terminal pro-brain natriuretic peptide versus electrophysiologic study for predicting future outcomes in patients with an implantable cardioverter defibrillator after myocardial infarction.
Yu H; Oswald H; Gardiwal A; Lissel C; Klein G
Am J Cardiol; 2007 Aug; 100(4):635-9. PubMed ID: 17697820
[TBL] [Abstract][Full Text] [Related]
12. Clinical Impact of Implantable Cardioverter-Defibrillator Therapy and Mortality Prediction Model for Effective Primary Prevention in Korean Patients.
Bae MH; Cho Y; Hwang J; Park HS; Han S; Lee YS; Cho HJ; Jung BC; Lee CH; Hyun DW; Park JS; Ahn J; Kim KH; Shin DG
J Korean Med Sci; 2020 Mar; 35(9):e49. PubMed ID: 32141247
[TBL] [Abstract][Full Text] [Related]
13. Outcomes After Implantable Cardioverter-Defibrillator Generator Replacement for Primary Prevention of Sudden Cardiac Death.
Madhavan M; Waks JW; Friedman PA; Kramer DB; Buxton AE; Noseworthy PA; Mehta RA; Hodge DO; Higgins AY; Webster TL; Witt CM; Cha YM; Gersh BJ
Circ Arrhythm Electrophysiol; 2016 Mar; 9(3):e003283. PubMed ID: 26921377
[TBL] [Abstract][Full Text] [Related]
14. N-Terminal Pro-B-Type Natriuretic Peptide in Risk Stratification of Heart Failure Patients With Implantable Cardioverter-Defibrillator.
Deng Y; Cheng SJ; Hua W; Cai MS; Zhang NX; Niu HX; Chen XH; Gu M; Cai C; Liu X; Huang H; Zhang S
Front Cardiovasc Med; 2022; 9():823076. PubMed ID: 35299981
[TBL] [Abstract][Full Text] [Related]
15. Role of N-terminal pro-B type natriuretic peptide as a predictor of poor outcomes in patients with HFrEF receiving primary prevention implantable cardioverter-defibrillator therapy: a systematic review and dose-response meta-analysis.
Prameswari HS; Putra ICS; Kamarullah W; Pranata R; Iqbal M; Karwiky G; Pramudyo M; Kusumawardhani NY; Achmad C; Martha JW; Akbar MR
Open Heart; 2023 Mar; 10(1):. PubMed ID: 36927867
[TBL] [Abstract][Full Text] [Related]
16. N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study.
Ezekowitz JA; O'Connor CM; Troughton RW; Alemayehu WG; Westerhout CM; Voors AA; Butler J; Lam CSP; Ponikowski P; Emdin M; Patel MJ; Pieske B; Roessig L; Hernandez AF; Armstrong PW
JACC Heart Fail; 2020 Nov; 8(11):931-939. PubMed ID: 33039447
[TBL] [Abstract][Full Text] [Related]
17. Implantable Cardioverter-Defibrillator Placement for Primary Prevention in 2,346 Patients: Predictors of One-Year Survival.
Merchant FM; Desai Y; Addish MA; Kelly K; Casey M; Goyal A; Leon AR; El-Chami MF
Tex Heart Inst J; 2018 Aug; 45(4):221-225. PubMed ID: 30374229
[TBL] [Abstract][Full Text] [Related]
18. Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy.
Coats CJ; Gallagher MJ; Foley M; O'Mahony C; Critoph C; Gimeno J; Dawnay A; McKenna WJ; Elliott PM
Eur Heart J; 2013 Aug; 34(32):2529-37. PubMed ID: 23455360
[TBL] [Abstract][Full Text] [Related]
19. Outcomes in African Americans undergoing cardioverter-defibrillator implantation for primary prevention of sudden cardiac death: findings from the Prospective Observational Study of Implantable Cardioverter-Defibrillators (PROSE-ICD).
Zhang Y; Kennedy R; Blasco-Colmenares E; Butcher B; Norgard S; Eldadah Z; Dickfeld T; Ellenbogen KA; Marine JE; Guallar E; Tomaselli GF; Cheng A
Heart Rhythm; 2014 Aug; 11(8):1377-83. PubMed ID: 24793459
[TBL] [Abstract][Full Text] [Related]
20. Baroreflex sensitivity assessed with the sequence method is associated with ventricular arrhythmias in patients implanted with a defibrillator for the primary prevention of sudden cardiac death.
Garcia R; Degand B; Fraty M; Le Marcis V; Bidegain N; Laude D; Tavernier M; Le Gal F; Hadjadj S; Saulnier PJ; Ragot S
Arch Cardiovasc Dis; 2019 Apr; 112(4):270-277. PubMed ID: 30670362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
